NCT05462990View on ClinicalTrials.gov

A Proof-of-concept Study to Examine QUC398 in Participants With Knee OA

PHASE2TerminatedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

November 9, 2022

Primary Completion Date

August 2, 2024

Study Completion Date

April 8, 2025

Conditions
Osteoarthritis, Knee
Interventions
DRUG

QUC398

QUC398 150 mg/mL, solution for s.c. injection (1 mL)

DRUG

Placebo

Placebo 0 mg/mL, solution for s.c. injection (1 mL)

Trial Locations (14)

2065

Novartis Investigative Site, St Leonards

2730

Novartis Investigative Site, Herlev

4222

Novartis Investigative Site, Southport

7100

Novartis Investigative Site, Vejle

8011

Novartis Investigative Site, Christchurch

15006

Novartis Investigative Site, A Coruña

28557

West Clinical Research, Morehead City

28915

Novartis Investigative Site, Leganés

33603

Clinical Research of West Florida Inc, Tampa

41010

Novartis Investigative Site, Seville

45100

Novartis Investigative Site, Orléans

02118

Boston Univ School Of Medicine, Boston

06001

Novartis Investigative Site, Nice

08208

Novartis Investigative Site, Sabadell

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY